Gene therapy of hypertensive vascular injury

被引：2

作者：

Chu Y. ^{[1
]}

Faraci F.M. ^{[2
]}

Heistad D.D. ^{[3
]}

机构：

[1] Cardiovascular Center, Department of Internal Medicine, University of Iowa, Iowa City

[2] Cardiovascular Center, Department of Internal Medicine and Pharmacology, University of Iowa College of Medicine, Iowa City

[3] Cardiovascular Center, Department of Internal Medicine and Pharmacology, University of Iowa, Iowa City

来源：

Current Hypertension Reports | 2000年 / 2卷 / 1期

关键词：

Gene Therapy; Gene Transfer; Vascular Injury; Atrial Natriuretic Peptide; Angiotensinogen;

D O I：

10.1007/s11906-000-0065-4

中图分类号：

学科分类号：

摘要：

Hypertension and vascular injury usually require prolonged treatment, and compliance is a key to efficacy for pharmacologically-based antihypertensive therapy. Gene therapy has the potential to be long lasting, with few side effects. Recent studies have provided promising results, in which hypertension can be treated by either augmentation of vasodilation or inhibition of vasocon-striction through gene transfer in experimental models. Gene transfer is also becoming useful for the study of mechanisms of physiologic and pathophysiologic conditions, including hypertension. In this mini-review, we summarize some recent studies in this area of research, and suggest some areas where progress is needed t advance the research toward gene therapy. Copyright © 2000 by Current Science Inc.

引用

页码：92 / 97

页数：5

共 50 条

[21] Lin K.F., Chao J., Chao L., Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats, Hypertension, 26, pp. 847-853, (1995)
[22] Lin K.F., Chao J., Chao L., Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats, Hypertension, 33, pp. 219-224, (1999)
[23] Lin K.F., Chao L., Chao J., Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery, Hypertension, 30, pp. 307-313, (1997)
[24] Gyurko R., Wielbo D., Phillips M.I., Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin, Regul Pept, 49, pp. 167-174, (1993)
[25] Phillips M.I., Wielbo D., Gyurko R., Antisense inhibition of hypertension: A new strategy for renin-angiotensin candidate genes, Kidney Int, 46, pp. 1554-1556, (1994)
[26] Wielbo D., Sernia C., Gyurko R., Phillips M.I., Antisense inhibition of hypertension in the spontaneously hypertensive rat, Hypertension, 25, pp. 314-319, (1995)
[27] Tomita N., Morishita R., Higaki J., Et al., Transient decrease in high blood pressure by in vivo transfer of antisense oligode-oxynucleotides against rat angiotensinogen, Hypertension, 26, pp. 131-136, (1995)
[28] Wielbo D., Simon A., Phillips M.I., Toffolo S., Inhibition of hypertension by peripheral administration of antisense oligonucleotides, Hypertension, 28, pp. 147-151, (1996)
[29] Makino N., Sugano M., Ohtsuka S., Sawada S., Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneosly hypertensive rats, Hyp Ertension, 31, pp. 1166-1170, (1998)
[30] Phillips M.I., Mohuczy-Dominiak D., Coffey M., Et al., Prolonged reduction of high blood pressure with an in vivo, nonpatho-genic, adeno-associated viral vector delivery of AT1-R mRNA antisense, Hypertension, 29, pp. 374-380, (1997)

← 1 2 3 4 5 →